Ultragenyx Pharma (RARE) Tops Q3 EPS by 8c, provides guidance

Ultragenyx Pharma (NASDAQ: RARE) reported Q3 EPS of ($1.40), $0.08 better than the analyst estimate of ($1.48). Revenue for the quarter came in at $139.45 million versus the consensus estimate of $135.28 million.

GUIDANCE:

Ultragenyx Pharma sees FY2024 revenue of $530-550 million, versus the consensus of $537 million.

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.

You May Also Be Interested In

• Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
• JPMorgan Starts Bechtle AG (BC8:GR) (BECTY) at Neutral
• Goldman Sachs Downgrades Vonovia SE (VNA:DR) (VNNVF) to Neutral